This is blowing my mind. I came to this forum because I was considering semaglutide for weight loss and was embarrassed about it — feeling like it's "cheating" or a "vanity drug." Reading about mortality reductions, cardiovascular protection, kidney protection... this reframes everything.

Is there any other single drug in medicine that simultaneously reduces weight, improves glucose, lowers blood pressure, improves lipids, reduces inflammation, protects the kidneys, and reduces mortality?

Honestly? No. I've been practicing endocrinology for 18 years and I have never seen a single drug class with this breadth of benefit across this many organ systems and outcomes. The closest historical parallel might be the early statin era, when we first realized that a single pill could reduce MI, stroke, and death. But even statins don't improve weight, blood pressure, glucose, or kidney function.

And please abandon the "cheating" narrative. Obesity is a chronic, relapsing, neurobiological disease with strong genetic determinants. Using a medication to treat it is no different from using insulin for type 1 diabetes or levothyroxine for hypothyroidism. The stigma around obesity medication is a cultural artifact, not a medical reality.

You're not cheating. You're treating a disease with an evidence-based therapy that happens to also extend your life. That's medicine working as intended.

To close with perspective: if we apply the SELECT mortality data (HR 0.81 for all-cause death) to the estimated 650 million adults with obesity worldwide, and assume even a fraction could be treated, the population-level impact is staggering.

For the United States alone, with approximately 100 million adults with obesity and established or at-risk CVD, a 19% relative mortality reduction could translate to prevention of an estimated 40,000-80,000 deaths annually, depending on uptake, adherence, and baseline risk.

For context, that's comparable to the estimated lives saved annually by all statin prescriptions in the US combined. GLP-1 agonists have the potential to be the most impactful pharmacological intervention for cardiovascular mortality since statins.

This thread captures exactly why this forum exists: to discuss the clinical evidence behind these medications with rigor, nuance, and respect for both the data and the patients who stand to benefit.

The SELECT mortality data, combined with FLOW's mortality signal, STEP-HFpEF's functional improvements, and the SURPASS program's metabolic data, collectively make the strongest case in modern medicine for a single drug class addressing multiple dimensions of cardiometabolic disease.

Pinned. This is a foundational thread for understanding the CV evidence behind GLP-1 receptor agonists.

I'll add a final thought. We are at a genuine inflection point in cardiometabolic medicine. Just as the statin revolution of the 1990s transformed secondary prevention, the GLP-1/GIP revolution of the 2020s is transforming how we think about the intersection of obesity, diabetes, cardiovascular disease, kidney disease, liver disease, and mortality.

The evidence is no longer theoretical or preliminary. SELECT (HR 0.80 for MACE, HR 0.81 for mortality), SUSTAIN-6 (HR 0.74 for MACE), FLOW (HR 0.76 for kidney composite, HR 0.80 for mortality), STEP-HFpEF (dramatic functional improvement) — these are not small, exploratory trials. These are large, well-powered, rigorously conducted trials published in the New England Journal of Medicine.^[1,2,3]

The question is no longer whether these drugs work. The question is how to ensure equitable access to the most important new drug class of our generation.

^[1] Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.
^[2] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.
^[3] Perkovic V, et al. N Engl J Med. 2024;391(2):109-121.